Ftse Mib
38.393,76
0,12%
DAX
22.459,94
0,11%
S&P 500
6.095,42
-0,79%
NASDAQ
19.871,22
-0,92%
Bitcoin
97.025,02
0,41%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Omeros Corporation (OMER) Omeros Corporation (OMER) Notizie

OMER

Omeros (OMER)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:OMER
DataOraFonteTitoloSimboloCompagnia
20/02/202515:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
20/02/202515:10Business WireOmeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMANASDAQ:OMEROmeros Corporation
14/02/202515:00Business WireOmeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem MeetingsNASDAQ:OMEROmeros Corporation
10/02/202515:00Business WireOmeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access ProgramNASDAQ:OMEROmeros Corporation
16/01/202515:15Business WireOmeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary EndpointNASDAQ:OMEROmeros Corporation
19/12/202415:15Business WireOmeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMANASDAQ:OMEROmeros Corporation
10/12/202414:45Business WireOmeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual MeetingNASDAQ:OMEROmeros Corporation
02/12/202414:45Business WireOmeros Corporation Announces Upcoming Presentations at ASH Annual MeetingNASDAQ:OMEROmeros Corporation
21/11/202415:15Business WireOmeros Corporation Provides Update on Progress Toward BLA ResubmissionNASDAQ:OMEROmeros Corporation
13/11/202422:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OMEROmeros Corporation
13/11/202422:02Business WireOmeros Corporation Reports Third Quarter 2024 Financial ResultsNASDAQ:OMEROmeros Corporation
11/11/202422:11Business WireOmeros Corporation to Announce Third Quarter Financial Results on November 13, 2024NASDAQ:OMEROmeros Corporation
24/10/202414:45Business WireFDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 GlomerulopathyNASDAQ:OMEROmeros Corporation
07/08/202422:02Business WireOmeros Corporation Reports Second Quarter 2024 Financial ResultsNASDAQ:OMEROmeros Corporation
05/08/202422:02Business WireOmeros Corporation to Announce Second Quarter Financial Results on August 7, 2024NASDAQ:OMEROmeros Corporation
07/06/202423:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
04/06/202415:00Business WireOmeros Announces Webcast Details for Annual Meeting of ShareholdersNASDAQ:OMEROmeros Corporation
03/06/202415:00Business WireOmeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028NASDAQ:OMEROmeros Corporation
15/05/202422:02Business WireOmeros Corporation Reports First Quarter 2024 Financial ResultsNASDAQ:OMEROmeros Corporation
10/05/202414:50Business WireOmeros Corporation to Announce First Quarter Financial Results on May 15, 2024NASDAQ:OMEROmeros Corporation
09/05/202414:50Business WireOmeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid CongressNASDAQ:OMEROmeros Corporation
01/04/202422:02Business WireOmeros Corporation Reports Fourth Quarter and Year-End 2023 Financial ResultsNASDAQ:OMEROmeros Corporation
27/03/202413:30Business WireOmeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024NASDAQ:OMEROmeros Corporation
20/02/202415:00Business WireOmeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic MicroangiopathyNASDAQ:OMEROmeros Corporation
14/02/202412:05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OMEROmeros Corporation
01/02/202415:11Business WireOmeros Corporation Announces Additional Royalty Monetization with DRI Healthcare TrustNASDAQ:OMEROmeros Corporation
29/01/202421:26Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:OMEROmeros Corporation
09/11/202322:02Business WireOmeros Corporation Reports Third Quarter 2023 Financial ResultsNASDAQ:OMEROmeros Corporation
06/11/202314:00Business WireOmeros Corporation to Announce Third Quarter Financial Results on November 9, 2023NASDAQ:OMEROmeros Corporation
03/11/202314:05Business WireOmeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic MicroangiopathyNASDAQ:OMEROmeros Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:OMER

La tua Cronologia

BIT
STMMI
ST Microelectronics
BIT
TEN
Tenaris
BIT
UCG
Unicredit
BIT
STLAM
Stellantis NV
BIT
LDO
Leonardo
BIT
ISP
Intesa Sanpaolo
BIT
CPR
Davide Campari
BIT
ENEL
Enel
BIT
BPE
Bper Banca
BIT
G
Generali
BIT
A2A
A2A
BIT
ENI
Eni
BIT
TIT
Telecom Italia
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BAMI
Banco BPM
BIT
RACE
Ferrari NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci